Burrows Scott L
SEC insider (Form 3/4/5 filer). CIK 0001853327. Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE). 40 reported Form 4/5 transactions since Sep 2024; latest on Oct 1, 2026. Located in WALTHAM, MA.
Companies Burrows Scott L has filed insider reports for
- Spyre Therapeutics, Inc. (SYRE): Officer, Chief Financial Officer
Burrows Scott L
CIK: 0001853327
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Spyre Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (40 total)
- Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect1.5K shares at avg. $90.27$135K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect229 shares at avg. $93.57$21K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect600 shares at avg. $89.07$53K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
ExerciseDirect7.5K shares at avg. $14.50$109K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect2.1K shares at avg. $91.92$193K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect3.1K shares at avg. $92.95$285K - Sep 30, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect17.5K shares at avg. $89.89$1.6M - Sep 30, 2026SYRE
Spyre Therapeutics, Inc.
ExerciseDirect17.5K shares at avg. $14.50$254K - Sep 2, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect18.2K shares at avg. $89.35$1.6M - Sep 1, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect2K shares at avg. $88.03$177K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 1,500 | $90.27 | $135,405 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 229 | $93.57 | $21,428 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 600 | $89.07 | $53,442 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Exercise | 7,500 | $14.50 | $108,750 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 2,100 | $91.92 | $193,032 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 3,071 | $92.95 | $285,449 | Direct |
| Sep 30, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 17,500 | $89.89 | $1,573,075 | Direct |
| Sep 30, 2026 | SYRE Spyre Therapeutics, Inc. | Exercise | 17,500 | $14.50 | $253,750 | Direct |
| Sep 2, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 18,232 | $89.35 | $1,629,029 | Direct |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 2,016 | $88.03 | $177,468 | Direct |
1-10 of 40 transactions